Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Statements of Stockholders' Equity (Unaudited)

v3.19.1
Consolidated Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Total
Beginning balance at Dec. 31, 2017 $ 1 $ 312 $ 97,114,659 $ (89,276,117) $ (450,734) $ 7,388,121
Beginning balance, shares at Dec. 31, 2017 1,378 3,119,445        
Stock-based compensation $ 10 329,515 329,525
Stock-based compensation, shares 98,350        
Conversion of Series E preferred stock $ (1) $ 89 (88)
Conversion of Series E preferred stock, shares (892) 892,386        
Common stock issued for acquisition of patents $ 6 959,994 960,000
Common stock issued for acquisition of patents, shares 62,500        
Issue common stock for conversion of Warrants $ 1 55,790 55,791
Issue common stock for conversion of Warrants, shares 4,433        
Common stock issuance related to note conversion $ 65 2,095,523 2,095,588
Common stock issuance related to note conversion, shares 654,871        
Currency translation gain 15 15
Net Loss (2,402,820) (2,402,820)
Ending balance at Mar. 31, 2018 $ 483 100,555,393 (91,678,937) (450,719) 8,426,220
Ending balance, shares at Mar. 31, 2018 486 4,831,985        
Beginning balance at Dec. 31, 2018 $ 638 105,461,396 (102,090,441) (450,719) 2,920,874
Beginning balance, shares at Dec. 31, 2018 6,379,992        
Stock-based compensation 282,180 282,180
Stock-based compensation, shares        
Par value adjustment and additional shares issued due to reverse split $ 1 (1)
Par value adjustment and additional shares issued due to reverse split, shares 5,413        
Net Loss (1,044,862) (1,044,862)
Ending balance at Mar. 31, 2019 $ 639 $ 105,743,575 $ (103,135,303) $ (450,719) $ 2,158,192
Ending balance, shares at Mar. 31, 2019 6,385,405